Surgeries & Interventions January 30, 2023
AVS Raises $20M for Calcified Arterial Disease January 30, 2023
Medical device startup AVS recently closed $20M in Series B funding to advance novel treatments for severely calcified arterial disease.
Artificial Intelligence January 26, 2023
Triaging Acute Chest Pain with Chest X-Ray AI January 26, 2023
Patients who arrive at the ED with acute chest pain (ACP) syndrome end up receiving a series of often-negative tests, but a new MGB-led study suggests that incorporating AI-based chest X-ray (CXR) analysis might make ACP triage more accurate and efficient.
Cardiovascular Disease Solutions January 23, 2023
Six-Year Study Sheds Light on Intermittent Fasting January 23, 2023
Does the timing of when one consumes their meals really matter, or is it merely the fact that eating within a tighter window encourages reduced caloric intake?
Surgeries & Interventions January 19, 2023
CAPLA: Simple Ablation is Best January 19, 2023
There is a tendency to think “more is better” when dealing with persistent AFib. This study adds to a growing body of evidence challenging that mindset.
Cardiology Business January 16, 2023
Wegovy Approved in Teens with Obesity January 16, 2023
Wegovy’s recent approval for adolescents is an exciting development with the potential to reduce long-term health risks associated with childhood obesity.
Cardiovascular Disease January 12, 2023
Unraveling the Vaccine-Myocarditis Mystery January 12, 2023
A new study published in Circulation suggests this phenomenon may be related to vaccine-generated spike proteins that dodged antibodies.
Cardiology Pharmaceuticals January 9, 2023
Repatha Re-analysis Raises Questions January 9, 2023
Amgen's PCSK9 inhibitor Repatha (evolocumab) is facing scrutiny after a reassessment of its FOURIER late-stage trial data revealed that the biologic may be associated with an increased risk of cardiovascular death.
Cardiovascular Disease January 4, 2023
Top 10 Cardiology Research Achievements of 2022 January 4, 2023
The American Heart Association recently revealed the top 10 most impressive advances in CVD research in 2022, from significant improvements in stroke care to pregnancy outcomes.
Cardiovascular Disease 20221216
Global CVD Almanac 20221216
JACC released a special “almanac-style” issue highlighting the growing burden of cardiovascular disease worldwide.
Guidelines December 15, 2022
Heart Disease Care in an Aging Population December 15, 2022
With the US facing an aging population, the AHA’s latest scientific statement provides timely information on the diagnosis and management of ACS in adults over 75.
Cardiovascular Disease December 12, 2022
Childhood Lp(a) Predicts Adult CVD Risk December 12, 2022
Individuals who had high Lp(a) levels when they were young were twice as likely to develop atherosclerotic cardiovascular disease in middle age.
Surgeries & Interventions December 8, 2022
Interventional Cardiology Joins The Match for 2025 December 8, 2022
Prospective IC fellows can breathe a sigh of relief. Starting in 2025, three-quarters of interventional cardiology fellowship programs will transition to a voluntary match system.
Guidelines December 5, 2022
Is 8 Minutes of Exercise Enough? December 5, 2022
A mere eight minutes of exercise a day – 54 minutes a week – is enough to lower risk of early death and heart disease.
Cardiovascular Disease December 1, 2022
ADHD Meds & Cardiovascular Disease December 1, 2022
New findings suggest ADHD medications — which have raised concerns about CVD risk — are safe for the heart.
Cardiology Pharmaceuticals November 28, 2022
FDA Warns 7 Supplement Companies for Illegally Claiming CV Benefits November 28, 2022
Just weeks after results from the SPORT trial showed no cholesterol benefit from common heart supplements, the FDA has issued warning letters to seven companies for illegally selling dietary supplements that claim to cure, treat, mitigate, or prevent cardiovascular disease.
Cardiology Pharmaceuticals November 21, 2022
Aprocitentan: The New Antihypertensive on the Block November 21, 2022
Aprocitentan has proved itself a promising new agent for blood pressure control. In the PRECISION trial, aprocitentan lowered both office and 24-hour ambulatory BP among people with resistant hypertension.
Surgeries & Interventions November 17, 2022
Cryoablation as a First-Line AFib Therapy November 17, 2022
Cryoablation outperforms antiarrhythmic drugs as a first-line defense against AFib.
Cardiology Pharmaceuticals November 14, 2022
SPORT: Statins Obliterate OTC Heart Supplements November 14, 2022
Six widely used dietary supplements promoted for improving heart health – including brands of fish oil, cinnamon, garlic and turmeric – were not as effective as rosuvastatin at lowering “bad” cholesterol more after 28 days of use.
Cardiology Pharmaceuticals November 10, 2022
Amgen’s Olpasiran Slashes Lp(a) Levels November 10, 2022
The Ocean(a)-DOSE trial made a splash at AHA this year, providing new insight into olpasiran’s potential to reduce Lp(a) levels in patients with ASCVD. In the phase 2 trial, 75 mg or more of the Amgen siRNA therapy delivered at least every three months basically obliterated Lp(a) levels.
